Women’s Health

While Cures Within Reach is disease-agnostic and geography-agnostic, some of our funding partners have strategic interests in specific population groups.  Therefore, in addition to our disease-specific and geographic repurposing communities, we have a Women’s Health Community (part of our overall Health Equity efforts) that utilizes the speed and cost-effectiveness of testing already approved therapies in new indications to improve the quality and length of life of women around the globe.

Our repurposing research and events within the Women’s Health Community all focus on connecting our many stakeholder groups together in our shared goal: driving more treatments to more patients more quickly through repurposing.

Our efforts include finding and funding clinical repurposing trials to quickly impact women’s health issues at any age, in any disease area.

Funding Opportunity RFPs for Women’s Health:

• ReGRoW: Funding for Under-resourced Researchers in Low and Lower-Middle Income Countries 2025: Women’s Health is eligible! Accepting budgets of up to US$65,000 for clinical repurposing trials in any disease led by an under-resourced researcher in any LMIC, as defined by the World Bank. SUBMISSIONS DUE MARCH 28, 2025.
• Read about our open RFP for Repurposing Research for Chicago 2025: accepting budgets of up to $100,000 for clinical repurposing trials from Chicago area research institutions. Women’s Health is eligible in several of the four Chicago RFP tracks. Specific focus areas for the other tracks include Health Equity, Early Stage Investigators, Pediatrics, Veterans/Military. DEADLINE EXTENDED: SUBMISSIONS DUE MAY 16, 2025.
• Repurposing Research to Improve Patient Outcomes in Meniere’s Disease and Related Diagnoses: Clinical and Preclinical Projects: for clinical repurposing trials (budgets up to $350,000) and preclinical repurposing research (budgets up to $100,000) in Meniere’s disease as well as other vertigo and hearing loss-related diagnoses, including benign paroxysmal positional vertigo (BPPV), tinnitus, labyrinthitis and vestibular neuritis. SUBMISSIONS DUE JUNE 13, 2025.

Our ongoing women’s health trials: